A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer Disease

Archives of Neurology

Volumn 66, Issue 2, 2009, Pages 190-199

  Xia, Weiming ^a,d   Yang, Ting ^a   Shankar, Ganesh ^a   Smith, Imelda M ^b   Shen, Yong ^c   Walsh, Dominic M ^b   Selkoe, Dennis J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; CYSTEINE; DISULFIDE; MERCAPTOETHANOL; MONOMER; OLIGOMER; PRESENILIN; SERINE;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; ASSAY; AUTOPSY; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MUTATION; NONHUMAN; PLASMA; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POLYMERS; PREDICTIVE VALUE OF TESTS; SENILE PLAQUES; SOLUBILITY;

EID: 60549107033     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.565     Document Type: Article

References (39)

1. portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J proteome Res. 2006;5(4):1010-1016.
2. Vigo-pelfrey C, Lee D, Keim pS, Lieberburg I, Schenk D. Characterization of p-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61(5): 1965-1968.
3. Jarrett JT, Berger Ep, Lansbury pT Jr. The carboxy terminus of the p amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32(18):4693-4697.
4. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44(1):181-193.
5. Blasko I, Jellinger K, Kemmler G, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid p 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2008; 29(1):1-11.
6. Mayeux R, Tang MX, Jacobs DM, et al. plasma amyloid p-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46(3):412-416.
7. Mayeux R, Honig LS, Tang MX, et al. plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185-1190.
8. Schupf N, patel B, pang D, et al. Elevated plasma β-amyloid peptide Aβ(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007; 64(7):1007-1013.
9. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the pre-senilin 1 and 2 and App mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
10. Ringman JM, Younkin SG, pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71(2):85-92.
11. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset alzheimer's disease pedigrees. Science. 2000;290(5500):2303-2304.
12. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Heritability of plasma amyloid β in typical late-onset alzheimer's disease pedigrees. Genet Epidemiol. 2001; 21(1):19-30.
13. Ertekin-Taner N, Younkin LH, Yager DM, et al. plasma amyloid β protein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70(8):596-606.
14. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13 (11):1359-1362.
15. Hye A, Lynham S, Thambisetty M, et al. proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129(pt 11):3042-3050.
16. Assini A, Cammarata S, Vitali A, et al. plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63(5):828-831.
17. Sundelöf J, Giedraitis V, I rizarry MC, et al. plasma β amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol. 2008;65(2):256-263.
18. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Aβ42/ Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64(3):354-362.
19. van Oijen M, Hofman A, Soares HD, Koudstaal pJ, Breteler MM. plasma Aβ(1-40) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-660.
20. Hansson O, Zetterberg H, Blennow K, et al. Evaluation of plasmaAβ(40) and Aβ (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment [published online ahead of print October 25,2008]. Neurobiol Aging. doi:10.1016/j.neurobiolaging. 2008.09.006.
21. Fullwood NJ, Hayashi Y, Allsop D. plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesis. Lancet Neurol. 2006;5(12):1000-1003.
22. Shankar GM, Li S, Mehta TH, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-842.
23. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. proc Natl Acad Sci USA. 1997;94(4):1550-1555.
24. Seubert p, Oltersdorf T, Lee MG, et al. Secretion of β-amyloid precursor protein cleaved at the amino-terminus of the β-amyloid peptide. Nature. 1993;361 (6409):260-263.
25. Xia W, Zhang J, Kholodenko D, et al. Enhanced production and oligomerization of the 42-residue amyloid p-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997;272(12):7977-7982.
26. Morishima-Kawashima M, Ihara Y. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry. 1998;37(44):15247-15253.
27. El-Agnaf OM, Mahil DS, patel Bp, Austen BM. Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun. 2000;273(3):1003-1007.
28. Howlett DR, perry AE, Godfrey F, et al. Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans. Biochem J. 1999;340(pt 1):283-289.
29. Hu MK, Liao YF, Chen JF, et al. New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins. Bioorg Med Chem. 2008;16(4):1957-1965.
30. podlisny MB, Ostaszewski BL, Squazzo SL, et al. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270(16):9564-9570.
31. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid β-protein fibrillogenesis: detection of aprotofib rillar intermediate. J Biol Chem. 1997;272(35):22364-22372.
32. Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. proc Natl Acad Sci U S A. 2005;102(7):2273-2276.
33. Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (App) transgenic mice. J Biol Chem. 2006;281(7):4292-4299.
34. Englund H, Sehlin D, Johansson AS, et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem. 2007;103(1):334-345.
35. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospi-nal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nonde-mented older adults. Arch Neurol. 2007;64(3):343-349.
36. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study [published correction appears in Lancet Neurol. 2006;5(4):293]. Lancet Neurol. 2006;5(3):228-234.
37. Stomrud E, Hansson O, Minthon L, Blennow K, Rosen I, Londos E. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years [published online ahead of print May 5, 2008]. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2008.03.025.
38. Craft DL, Wein LM, Selkoe DJ. A mathematical model of the impact of novel treatments on the Aβ burden in the Alzheimer's brain, CSF and plasma. Bull Math Biol. 2002;64(5):1011-1031.
39. Crystal HA, Davies p. Toward a plasma marker for Alzheimer disease: some progress, but still a long way to go. Neurology. 2008;70(8):586-587.